About: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 February 2017

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2017 (ast) наукова стаття, опублікована в лютому 2017 (uk) مقالة علمية نشرت في 27 فبراير 2017 (ar) scientific article published on 27 February 2017 (en)
publication date	wds:Q37668253-9F01389B-9AC5-4BCA-8422-2CB4EBFBA576
publication date	2017-02-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37668253-ED18F703-54A2-46B2-8141-CE115B3B28B9
language of work or name	English
exact match	wds:Q37668253-E8F792B9-AE8F-4C09-81BB-7C69FA25EE26
exact match	https://scigraph.springernature.com/pub.10.1186/s12933-017-0511-0
cites work	wds:Q37668253-046DDACF-3790-4F4F-BFD8-1256F7E608CF wds:Q37668253-054D3190-6EE0-4BB9-A3CD-A175C1212669 wds:Q37668253-0B3FD92B-71C7-4192-8453-201DA12D852E wds:Q37668253-0FE7C38F-622F-452E-AE1D-18666B7B908E wds:Q37668253-11D705FB-71D2-4DB3-8DCE-37FDF9937026 wds:Q37668253-18B9B41D-4AD1-4E85-B52C-BEB217675A21 wds:Q37668253-1A0D2D15-2701-468F-9E4C-B1052CDA4C2D wds:Q37668253-2ADDA9AD-2BD5-47EA-8FB6-C74892B1FA62 wds:Q37668253-2B6321C1-BC39-4988-9A4F-4074D41105F7 wds:Q37668253-335BE43F-B464-40BC-A14B-B895934146C5 wds:Q37668253-367FB4D8-CA8A-4058-A394-082A21B62D71 wds:Q37668253-44EF3DD6-800E-41EB-9183-F8D59B9407CD wds:Q37668253-48BEEB43-FCB3-4AC8-8280-6CF020979A11 wds:Q37668253-4B774414-2BD8-48AB-BC37-FBB2D0F1C5C1 wds:Q37668253-5AB69A0F-8ADD-4BA8-93A0-9F3C02ABC3D5 wds:Q37668253-5DCCB8FF-B312-4095-972F-AD64F6B5B980 wds:Q37668253-6827E082-A298-44E2-94A9-E34A675226F3 wds:Q37668253-69F79C08-6D4F-4C76-9C44-D6B9CC749A8F wds:Q37668253-87AED272-DCD2-4BAA-A7D3-5B53B9A4AE72 wds:Q37668253-893333F6-9242-4B15-8B20-1F7E16C0C6F8 wds:Q37668253-8BDCB61E-0DC8-474D-AF19-7F48EAEA59BE wds:Q37668253-9D689FC9-E108-4BC9-8460-5E648247A534 wds:Q37668253-A4B228A5-5B8D-4433-A688-23A9CFE1019D wds:Q37668253-A937EDC0-8BC8-4350-985E-107DDA633A65 wds:Q37668253-AB950241-3C2F-48A5-912E-0D77E0E0B38A wds:Q37668253-B48512C9-B9A2-41CD-A25B-F1E3ACB429AA wds:Q37668253-B64B2C00-D8E2-4931-866E-66E463C82D93 wds:Q37668253-CAF2FAC3-AD39-4E91-8D96-FD6F2CFBAC54 wds:Q37668253-CCF224D3-FD51-4C00-90F4-A842457DC328 wds:Q37668253-D26D8025-E4D1-4D49-AD8C-16F4F46D7FDB wds:Q37668253-D6F5F936-43CC-4B68-8939-0D52E61C093F wds:Q37668253-D7381241-9557-499E-AF8F-C5DFDBC03E74 wds:Q37668253-D847AB9E-D3D1-44CD-ABDF-ADC1810EAA7B wds:Q37668253-E4F88E9E-E8F2-4E50-9683-5758882F5FDE wds:Q37668253-E9EECF35-CFA1-45FB-BEF5-6A48856AA106 wds:Q37668253-ECEC1869-A7A4-4A0C-AD4F-5CB791B578E4 wds:Q37668253-F1202E9C-0F6A-4B57-9B3C-171425529945
cites work	Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR). Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus Blood pressure targets for hypertension in people with diabetes mellitus Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-analysis Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes Type 2 diabetes mellitus and hypertension: an update Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants Double product and end-organ damage in African and Caucasian men: the SABPA study Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial Interaction between Mean Arterial Pressure and HbA1c in Prediction of Cardiovascular Disease Hospitalisation: A Population-Based Case-Control Study
author name string	wds:Q37668253-0ABFA16B-D587-4082-9B15-54F0C2E178D9 wds:Q37668253-47AC5DE0-E235-4BBC-A830-3F5A4AE355EA wds:Q37668253-5A31BFA0-1A8F-4A70-B0E8-77EE3AF2246C

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software